1,3-二(羟基甲基)-1,3-二氢-2H-苯并咪唑-2-硫酮 | 6028-35-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,3-二(羟基甲基)-1,3-二氢-2H-苯并咪唑-2-硫酮
• 英文名称: 1,3-bishydroxymethylbenzimidazoline-2-thione
• 英文别名: 1,3-di(hydroxymethyl)-2,3-dihydro-1H-benzo[d]imidazole-2-thione；1.3-Bis-hydroxymethyl-2-thion-benzimidazolin；Thyreocordor；Thyreocordon；1,3-bis-hydroxymethyl-1,3-dihydro-benzoimidazole-2-thione；1,3-bis-hydroxymethyl-1,3-dihydro-benzimidazole-2-thione；1,3-Bis-hydroxymethyl-1,3-dihydro-benzimidazol-2-thion；2-Mercaptobenzimidazol-N,N'-dimethylol；Thibenzazoline；1,3-bis(hydroxymethyl)benzimidazole-2-thione
• CAS: 6028-35-9
• 化学式: C₉H₁₀N₂O₂S
• mdl: MFCD00456344
• 分子量: 210.257
• InChiKey: GQXDJKKLSSXFMP-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162°

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  79
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,3-二(羟基甲基)-1,3-二氢-2H-苯并咪唑-2-硫酮 在 氯化亚砜 、 乙醇 、 sodium ethanolate 作用下， 生成 1,3-双(乙氧基甲基)-1,3-二氢-2H-苯并咪唑-2-硫酮
  参考文献：
  名称：

  Zinner et al., Chemische Berichte, 1957, vol. 90, p. 2852,2854

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-bis[(dimethylamino)methyl]-1,3-dihydro-2H-benzimidazole-2-thione 在 溶剂黄146 作用下， 生成 1,3-二(羟基甲基)-1,3-二氢-2H-苯并咪唑-2-硫酮
  参考文献：
  名称：

  Zinner et al., Chemische Berichte, 1957, vol. 90, p. 2852,2854

  摘要：

  DOI：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Ink-jet recording method
  申请人：Fuji Photo Film Co., Ltd.

  公开号：EP1459901A2

  公开（公告）日：2004-09-22

  An ink-jet recording method using an ink set for forming an image on an ink-jet recording medium, wherein the ink-jet recording medium has an ink-receiving layer which contains a sulfur-containing compound and is disposed on a support, the ink set contains a yellow ink containing a yellow dye, a magenta ink containing a magenta dye, and a cyan ink containing a cyan dye, as essential components, and the magenta dye has an oxidation potential of higher than 0.8 V (vs SCE).

  一种使用墨水组在喷墨记录介质上形成图像的喷墨记录方法，其中喷墨记录介质具有包含含硫化合物的受墨层，该受墨层设置在支撑物上，墨水组包含作为基本成分的包含黄色染料的黄色墨水、包含品红色染料的品红色墨水和包含青色染料的青色墨水，品红色染料的氧化电位高于 0.8 V（vs SCE）。